Price
1,202.5
+4.46%52W Range
Market Cap
₹1,032.07 Cr
Traded: ₹2.19 Cr (0.21%) 0.0x
Free Float: ₹435.33 Cr (0.50% of FF traded)
Volume · 60D trend
18.55 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
57 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +27.0% | +18.0% | +18.0% | -- | -- | Stable |
| Sales | +23.0% | -9.0% | +32.0% | -- | +47.0% | Accelerating |
| Profit | +68.0% | -12.0% | +31.0% | -- | +23.0% | Stable |
| Return | +62.0% | +25.0% | +43.0% | -19.0% | -- | Stable |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 35 | 50 | 34 | 22 | 23 | 25 | 29 | 19 | 23 | 18 | 19 | 14 | 18 |
| Expenses | 25 | 27 | 29 | 19 | 10 | 15 | 10 | 13 | 8 | 13 | 9 | 11 | 8 | 11 |
| Operating Profit | 9 | 8 | 22 | 15 | 12 | 8 | 15 | 16 | 11 | 10 | 9 | 8 | 6 | 7 |
| OPM % | 25.4% | 24.0% | 43.1% | 43.5% | 53.2% | 35.2% | 59.4% | 55.5% | 56.4% | 43.0% | 50.2% | 40.6% | 45.1% | 41.2% |
| Other Income | 6 | 10 | 6 | 6 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 13 | 15 | 27 | 20 | 16 | 13 | 18 | 19 | 14 | 14 | 11 | 10 | 9 | 8 |
| Tax % | 32.1% | 33.1% | 16.4% | 23.3% | 20.3% | 35.9% | 24.2% | 23.0% | 21.3% | 36.0% | 23.7% | 26.0% | 21.6% | 37.8% |
| Net Profit | 9 | 10 | 22 | 15 | 13 | 8 | 13 | 15 | 11 | 9 | 9 | 8 | 7 | 5 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 11.1 | 11.1 | 25.3 | 17.1 | 14.7 | 9.8 | 15.6 | 17.1 | 13.0 | 10.3 | 10.2 | 10.5 | 9.7 | 7.7 |
| Sales Growth (YoY) | 51.0% | 57.0% | 98.0% | 16.0% | 14.0% | -2.0% | 44.0% | 52.0% | 36.0% | 27.0% | 20.0% | 11.0% | 22.0% | -2.0% |
| Sales Growth (QoQ) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| OP Growth (YoY) | -28.0% | 7.2% | 44.1% | -8.9% | 8.0% | -19.8% | 69.9% | 107.6% | 70.0% | 32.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 0.4% | -60.9% | 47.5% | 24.5% | 49.4% | -47.4% | -6.8% | 47.7% | 10.8% | 11.4% | 13.9% | 21.0% | -13.7% | -- |
| Profit Growth (YoY) | -- | 13.8% | 62.2% | 0.4% | 13.1% | -5.3% | 53.7% | 86.6% | 52.7% | 52.9% | 29.6% | -6.7% | 80.0% | 39.8% |
| EPS Growth (YoY) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| OP Margin | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Margin | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Material Cost % | 22.5% | 21.3% | 26.8% | 27.3% | 25.0% | 34.0% | 22.4% | 26.2% | 24.0% | 26.9% | 28.2% | 35.1% | 27.6% | 27.2% |
| Employee Cost % | 25.5% | 26.4% | 16.3% | 13.7% | 8.0% | 8.5% | 6.7% | 7.1% | 8.3% | 7.0% | 8.9% | 9.8% | 10.1% | 8.4% |
| P/S | 6.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 18.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.18 | 3.24 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Newspaper Publication of Unaudited Financial Results for the quarter ended 30th June, 2026
Outcome of Board Meeting held on 13th August, 2026
Unaudited Financial Results for the quarter ended 30th June, 2026
Investor''s Presentation
3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and ....
Intimation to the holders of physical securities to furnish KYC details
Special Window for Re-lodgement of Transfer Requests of physical shares
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Closure of Trading Window
Disclosure under Regulation 29 (2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhirendra Dubey
Newspaper Publication for Transfer of Unclaimed Dividend/Equity Shares to IEPF Authority
Specimen of letter sent to shareholders whose shares are liable to be transferred to IEPF
Audio Recording of Analysts/Investors Call pertaining to the Audited Financial Results for the quarter and financial year ended March 31, 2026
Submission of Newspaper Publication
Outcome of Board Meeting held today i.e. 29th May, 2026
Investor''s Presentation
Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March, 2026
Intimation of Earning Concall under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.
Annual Secretarial Compliance Report for the year ended 31st March, 2026
3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Special Window for Re-lodgement of Transfer Requests of Physical Shares
Securities of the Companies permitted to trade and admitted to dealings on the National Stock Exchange
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Disclosure Under Regulation 31(4) of SEBI (SAST) Regulations, 2011
Newspaper Publication regarding Second "100 Days Campaign - Saksham Niveshak"
Closure of Trading Window
Outcome of Schedule of Analyst/ Investor Meeting
Schedule of Analyst/ Investor Meeting
Special Window for Re-lodgement of Transfer Requests of Physical shares
Transcript of Analysts/Investors Call pertaining to the Financial Results for the third quarter and nine months ended December 31, 2025
Audio Recording of Analysts/Investors Call pertaining to the Unaudited Financial Results for the third quarter and nine months ended December 31, 2025
Letter for Updation
Intimation of Re-Scheduling of the Earning Concall under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.
Submission of Advertisement Clipping of the extract of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2025
Submission of Unaudited Financial Results of the Company for the quarter and Nine Months ended December 31, 2025
Intimation of Earning Concall under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.
Investor''s Presentation
Submission of Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025
3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve the Unaudited Standalone and ....
Certificate under Reg.74(5) of SEBI (DP)Regulations, 2018
Special Window for Re-lodgement of Transfer Requests of Physical Shares
Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mahesh Kumar Upadhyay
Disclosure Under Regulation 29(2) of SEBI (SAST) Regulations, 2011
Outcome of Schedule of Analyst/ Investor Meeting
Special window for Re-lodgement of Transfer Requests of Physical Shares
Held by ETFs
1 ETFs hold 3bblackbio · sorted by weight
Held by Mutual Funds
1 schemes hold 3bblackbio · sorted by weight